Aspargo Labs, Inc. (AAGO)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	n/a
Revenue (ttm)	102,654
Net Income	-22.36M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About AAGO

Aspargo is a commercial stage specialty pharmaceutical and med-tech company focused on designing, developing and marketing proprietary, oral liquid suspension formulations of leading oral solid dose prescription and over-the-counter medications dispensed through “smart”, digitally connected, container closure drug delivery systems and associated mobile apps. Our first commercial product, Sildenafil Oral Suspension, indicated for the treatment of erectile dysfunction (ED), is an oral liquid suspension formulation of sildenafil citrate, administe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 11
• Stock Exchange: NYSE
• Ticker Symbol: AAGO
• Website: https://aspargolabs.com/

Financial Performance

Data Source: SEC filings Last updated: Aug 13, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error